Press

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

Nov 2 • 2 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonFormat: Industry PanelDate and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ETConference link: Financial Times’ Pharma and Biotech Summit…

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Nov 2 • 2 min read

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce announced the voting results from its Annual General and Special Meeting of Shareholders held on Monday, October 31 2022. A total of 16.55%…

Revitalist Increases Patient Access Making Care More Affordable by Financing the Cost With M-Lend Financial

Nov 1 • 2 min read

Revitalist Lifestyle and Wellness LTD. (CSE: CALM | OTCQB: RVLWF | FSE: 4DO), partners with patient financing company allowing client lending up to $100,000 USD per patient covering all Revitalist services including those related to ketamine and psychedelic medicine. Revitalist partners with M-Lend Financial allowing clients to participate in financial lending up to an 84…

Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

Nov 1 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced an upcoming presentation at the Neuropsychiatric & Psychedelics Drug Development Summit taking place October 31 to November 2, 2022, in Boston, MA. The presentation, titled “CYB004-Modifications to DMT to Enhance its Therapeutic Potential,” will highlight preclinical data for CYB004,…

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

Nov 1 • 4 min read

PharmaTher Holdings Ltd. (OTCQB: PHRRF | CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the Company has entered into an evaluation and exclusive option agreement (the “Agreement”) with Case Western Reserve University…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435